Enzymatic activity of PBP1B is required for growth rate-independent ppGpp-mediated resistance to PBP2 inhibitors in E. coli. [PDF]
Anderson SE, Mack IE, Levin PA.
europepmc +1 more source
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]
Pogue JM +3 more
europepmc +1 more source
Unraveling the mechanisms behind the enhanced efficacy of β-lactam-based sideromycins. [PDF]
Lacasse E +8 more
europepmc +1 more source
Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]
Dorazio AJ +5 more
europepmc +1 more source
Genomic characterization of multidrug-resistant <i>Escherichia coli</i> with PBP3 insertions carrying <i>bla</i><sub>NDM-5</sub> carbapenemase isolated from infants in Kenya. [PDF]
Kariuki K +10 more
europepmc +1 more source
Comparative <i>in vitro</i> efficacy of aztreonam-avibactam and other alternatives (cefepime-taniborbactam, cefepime-zidebactam, and cefiderocol) against metallo-β-lactamase-producing Enterobacterales isolated in 2024 in France. [PDF]
Emeraud C, Dutkiewicz M, Dortet L.
europepmc +1 more source
<i>In vivo</i> evolution of ceftazidime-avibactam resistance in <i>bla</i> <sub>OXA-244</sub>-positive <i>E. coli</i> potentially linked to PBP3 insertion and mutations in <i>acrB</i> and PBP2. [PDF]
Kocer K +4 more
europepmc +1 more source
How I manage patients with New Delhi metallo-beta-lactamase and OXA-48-producing Enterobacterales infections: a practical approach. [PDF]
Tiseo G, Galfo V, Falcone M.
europepmc +1 more source
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]
Tascini C +3 more
europepmc +1 more source
FtsK is critical for the assembly of the unique divisome complex of the FtsZ-less <i>Chlamydia trachomatis</i>. [PDF]
Harpring M +4 more
europepmc +1 more source

